{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T16:44:53.623837+00:00","company":{"ticker":"ALLR","cik":1860657,"company_name":"Allarity Therapeutics, Inc."},"pagination":{"limit":100,"returned":100,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"3i, LP","detail":"notes_offering","count":12,"first_seen":"2022-11-25T23:59:59+00:00","last_seen":"2024-03-15T23:59:59+00:00","evidence_fact_ids":[66956,70373,75086,79672,80723,134293,145370,163492,166117,185102,191950,194387]},{"display_name":"A.G.P./Alliance Global Partners","detail":"underwriting","count":2,"first_seen":"2023-04-25T23:59:59+00:00","last_seen":"2023-07-11T23:59:59+00:00","evidence_fact_ids":[132757,163491]},{"display_name":"Ascendiant Capital Markets, LLC","detail":"atm_program","count":1,"first_seen":"2024-03-20T23:59:59+00:00","last_seen":"2024-03-20T23:59:59+00:00","evidence_fact_ids":[65972]},{"display_name":"Eisai, Inc.","detail":"license","count":1,"first_seen":"2023-06-01T23:59:59+00:00","last_seen":"2023-06-01T23:59:59+00:00","evidence_fact_ids":[145369]},{"display_name":"Novartis Pharma AG","detail":"license","count":1,"first_seen":"2024-02-01T23:59:59+00:00","last_seen":"2024-02-01T23:59:59+00:00","evidence_fact_ids":[77860]},{"display_name":"Streeterville Capital, LLC","detail":"credit_facility","count":1,"first_seen":"2026-03-06T23:59:59+00:00","last_seen":"2026-03-06T23:59:59+00:00","evidence_fact_ids":[29780]},{"display_name":"Tumim Stone Capital LLC","detail":"equity_purchase","count":1,"first_seen":"2026-01-29T23:59:59+00:00","last_seen":"2026-01-29T23:59:59+00:00","evidence_fact_ids":[34201]},{"display_name":"the investors who acquired securities in the April Offering","detail":"equity_purchase","count":1,"first_seen":"2023-07-11T23:59:59+00:00","last_seen":"2023-07-11T23:59:59+00:00","evidence_fact_ids":[132758]}],"lender":[{"display_name":"3i, LP","detail":"convertible_notes","count":5,"first_seen":"2023-04-12T23:59:59+00:00","last_seen":"2024-03-15T23:59:59+00:00","evidence_fact_ids":[66957,75088,80724,134294,166118]},{"display_name":"Streeterville Capital, LLC","detail":"loan","count":1,"first_seen":"2026-03-06T23:59:59+00:00","last_seen":"2026-03-06T23:59:59+00:00","evidence_fact_ids":[26142]}]},"facts":[{"fact_type":"earnings_release","fact_key":"89b2b8e49dba2b8e7938ff9a99d4b00cebc6dbe4","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":null},"claim":"Allarity Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.","evidence_excerpt":"On March 31, 2026, Allarity Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the fiscal year ended December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-038061","anchor_url":"https://secwatch.observer/filing/0001213900-26-038061#claim-89b2b8e49dba2b8e7938ff9a99d4b00cebc6dbe4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/0001213900-26-038061-index.htm"},{"fact_type":"material_agreement","fact_key":"2ed43a922b72a2042543758eb2fafac44058eb15","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-03-06T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Note Purchase Agreement","agreement_type":"credit_facility","counterparty":"Streeterville Capital, LLC","effective_date":"2026-03-02","item_codes_triggered":["1.01"],"value_text":"$20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000)"},"claim":"Allarity Therapeutics, Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000) (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001213900-26-024339","anchor_url":"https://secwatch.observer/filing/0001213900-26-024339#claim-2ed43a922b72a2042543758eb2fafac44058eb15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm"},{"fact_type":"debt_financing","fact_key":"40d6764414716792a8fd029130a8d142a6fcff72","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-03-06T23:59:59+00:00","payload":{"counterparty":"Streeterville Capital, LLC","effective_date":"2026-03-02","event":"incurrence","instrument_type":"loan","interest_rate_text":"9.00% per annum and 5.00% per annum","item_codes_triggered":["2.03"],"maturity_text":"18 months following the date of issuance","principal_text":"$10,930,000 (A-1 Note) and $10,000,000 (B Note)"},"claim":"Allarity Therapeutics, Inc. incurred loan of $10,930,000 (A-1 Note) and $10,000,000 (B Note) with Streeterville Capital, LLC at 9.00% per annum and 5.00% per annum maturing 18 months following the date of issuance.","evidence_excerpt":"On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-024339","anchor_url":"https://secwatch.observer/filing/0001213900-26-024339#claim-40d6764414716792a8fd029130a8d142a6fcff72","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026024339/0001213900-26-024339-index.htm"},{"fact_type":"material_agreement","fact_key":"79e99846e0d6378aa9855ab8e166572516012638","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-01-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Common Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Tumim Stone Capital LLC","effective_date":"2026-01-28","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. entered into Common Stock Purchase Agreement with Tumim Stone Capital LLC (effective 2026-01-28).","evidence_excerpt":"On January 28, 2026, Allarity Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with Tumim Stone Capital LLC, a Delaware limited liability company (the “ Investor ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-009157","anchor_url":"https://secwatch.observer/filing/0001213900-26-009157#claim-79e99846e0d6378aa9855ab8e166572516012638","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026009157/0001213900-26-009157-index.htm"},{"fact_type":"equity_issuance","fact_key":"0566ac292a888e59efdfa2c8bb2166ad7427d219","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-12-23T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$0.98 per Share","effective_date":"2025-12-23","item_codes_triggered":["3.02"],"purchaser":"a certain accredited investor","security_type":"common_stock","shares_text":"255,103 shares"},"claim":"Allarity Therapeutics, Inc. issued 255,103 shares of common stock to a certain accredited investor for $0.98 per Share.","evidence_excerpt":"At the Additional Closing, the Company agreed to issue and sell 255,103 shares (the “Additional Shares”) of the Company’s Common Stock, for $0.98 per Share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-124935","anchor_url":"https://secwatch.observer/filing/0001213900-25-124935#claim-0566ac292a888e59efdfa2c8bb2166ad7427d219","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025124935/0001213900-25-124935-index.htm"},{"fact_type":"equity_issuance","fact_key":"26eb49c505ba4c54742d7e142bdc449e637b537c","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$0.0001 exercise price per Pre-Funded Warrant; purchase price $1.5999 per Pre-Funded Warrant","effective_date":null,"item_codes_triggered":["3.02"],"purchaser":"a certain accredited investor","security_type":"warrant","shares_text":null},"claim":"Allarity Therapeutics, Inc. issued warrant to a certain accredited investor for $0.0001 exercise price per Pre-Funded Warrant; purchase price $1.5999 per Pre-Funded Warrant.","evidence_excerpt":"the Company has agreed to issue and sell 1,562,500 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for $1.60 per Share, and/or pre-funded warrants in (the “Pre-Funded Warrants) to purchase one share of Common Stock per Pre-Funded Warrant, at an offering price of $1.5999 per Pre-Funded Warrant (the “Purchase Price”), for gross proceeds to the Company of approximately $2.5 million, before deducting fees and expenses.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-090197","anchor_url":"https://secwatch.observer/filing/0001213900-25-090197#claim-26eb49c505ba4c54742d7e142bdc449e637b537c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/0001213900-25-090197-index.htm"},{"fact_type":"equity_issuance","fact_key":"7c402df53d46ee644895a8f8adcb10b653fc3b21","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$1.60 per Share, for gross proceeds of approximately $2.5 million","effective_date":null,"item_codes_triggered":["3.02"],"purchaser":"a certain accredited investor","security_type":"common_stock","shares_text":"1,562,500 shares"},"claim":"Allarity Therapeutics, Inc. issued 1,562,500 shares of common stock to a certain accredited investor for $1.60 per Share, for gross proceeds of approximately $2.5 million.","evidence_excerpt":"the Initial Closing, the Company has agreed to issue and sell 1,562,500 shares (the\n“Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for $1.60\nper Share, and/or pre-funded warrants in (the “Pre-Funded Warrants) to purchase one share of Common Stock per Pre-Funded\nWarrant, at an offering price of $1.5999 per Pre-Funded","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-090197","anchor_url":"https://secwatch.observer/filing/0001213900-25-090197#claim-7c402df53d46ee644895a8f8adcb10b653fc3b21","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/0001213900-25-090197-index.htm"},{"fact_type":"executive_change","fact_key":"b04592fe3a","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-30","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jesper Høiland was appointed as director at Allarity Therapeutics, Inc..","evidence_excerpt":"On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-25-020081","anchor_url":"https://secwatch.observer/filing/0001437749-25-020081#claim-b04592fe3a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020081/0001437749-25-020081-index.htm"},{"fact_type":"executive_change","fact_key":"fe9c8c7e24","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-06-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-30","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joseph W. Vazzano resigned as director at Allarity Therapeutics, Inc..","evidence_excerpt":"On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001437749-25-020081","anchor_url":"https://secwatch.observer/filing/0001437749-25-020081#claim-fe9c8c7e24","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925020081/0001437749-25-020081-index.htm"},{"fact_type":"executive_change","fact_key":"0f6f101e17","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-10-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-30","interim":false,"role":"President and Chief Development Officer","role_category":"president","successor_name":null,"successor_named":false},"claim":"Jeremy R. Graff was appointed as President and Chief Development Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-030661","anchor_url":"https://secwatch.observer/filing/0001437749-24-030661#claim-0f6f101e17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000143774924030661/0001437749-24-030661-index.htm"},{"fact_type":"executive_change","fact_key":"c3e741c96b","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-09-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-12","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Alexander Epshinsky was appointed as Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On September 12, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Alexander Epshinsky as the Chief Financial Officer of the Company as of September 12, 2024, succeeding Ms. Brown.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-078294","anchor_url":"https://secwatch.observer/filing/0001213900-24-078294#claim-c3e741c96b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024078294/0001213900-24-078294-index.htm"},{"fact_type":"executive_change","fact_key":"724ee19254","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-09-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-12","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Alexander Epshinsky","successor_named":true},"claim":"Joan Y. Brown resigned as Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-24-078294","anchor_url":"https://secwatch.observer/filing/0001213900-24-078294#claim-724ee19254","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024078294/0001213900-24-078294-index.htm"},{"fact_type":"earnings_release","fact_key":"f0302d1362fb97d275e607135a96b6a87611bbbb","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"-$3.8 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Allarity Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income -$3.8 million.","evidence_excerpt":"Net loss was $3.8 million for the quarter ended March 31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-043238","anchor_url":"https://secwatch.observer/filing/0001213900-24-043238#claim-f0302d1362fb97d275e607135a96b6a87611bbbb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/0001213900-24-043238-index.htm"},{"fact_type":"governance_change","fact_key":"80d76150929d8fe192d5c7831e5fefb5f66450c2","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-04-09","item_codes_triggered":["5.03"],"summary_text":"Filed Fifth Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock"},"claim":"Allarity Therapeutics, Inc.: Filed Fifth Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2024-04-09).","evidence_excerpt":"On April 4, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”) filed a Fifth Certificate of Amendment to Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 9:30 a.m. (Eastern Time) on April 9, 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-030473","anchor_url":"https://secwatch.observer/filing/0001213900-24-030473#claim-80d76150929d8fe192d5c7831e5fefb5f66450c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm"},{"fact_type":"shareholder_vote","fact_key":"683db28d2f444998356e848a72f5539e097e5c01","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approve adjournment of special meeting to solicit additional proxies in favor of Reverse Stock Split Proposal","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"4,143","votes_against":"1,130,018","votes_for":"4,598,095","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved Approve adjournment of special meeting to solicit additional proxies in favor of Reverse Stock Split Proposal.","evidence_excerpt":"Proposal 3 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 4,598,095 1,130,018 4,143 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-030473","anchor_url":"https://secwatch.observer/filing/0001213900-24-030473#claim-683db28d2f444998356e848a72f5539e097e5c01","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d3e73530098c95bb849d35d64e05a8c778a88972","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approve amendment to Certificate of Incorporation to effect reverse stock split at ratio between 1:5 and 1:20","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"16,902","votes_against":"1,095,954","votes_for":"4,619,400","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect reverse stock split at ratio between 1:5 and 1:20.","evidence_excerpt":"Proposal 2 : To approve an amendment to the Allarity Therapeutics, Inc. Certificate of Incorporation, as amended (the “Charter Amendment”), in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-5 and 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 4,619,400 1,095,954 16,902 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-030473","anchor_url":"https://secwatch.observer/filing/0001213900-24-030473#claim-d3e73530098c95bb849d35d64e05a8c778a88972","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b7754631a2b3f21b343d636a6ba2a9a0c79f1e59","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approve amendment to 2021 Equity Incentive Plan to increase authorized shares by 1,000,000","proposal_type":"equity_plan","results":[{"broker_non_votes":"1,537,390","subject":null,"votes_abstain":"1,917","votes_against":"294,784","votes_for":"3,898,165","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to 2021 Equity Incentive Plan to increase authorized shares by 1,000,000.","evidence_excerpt":"Proposal 1 : To approve an amendment to the Allarity Therapeutics, Inc. 2021 Equity Incentive Plan, a copy of such amended and restated plan is included as Appendix A to the Proxy Statement (the “2021 Plan”), to increase the aggregate number of shares of Common Stock authorized for issuance by 1,000,000 shares (the “Amendment to the 2021 Plan Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 3,898,165 294,784 1,917 1,537,390","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-030473","anchor_url":"https://secwatch.observer/filing/0001213900-24-030473#claim-b7754631a2b3f21b343d636a6ba2a9a0c79f1e59","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm"},{"fact_type":"material_agreement","fact_key":"169cbd5660fb3c33ca74130400178659f67cf0a5","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At-The-Market Issuance Sales Agreement","agreement_type":"atm_program","counterparty":"Ascendiant Capital Markets, LLC","effective_date":"2024-03-19","item_codes_triggered":["1.01"],"value_text":"up to $947,000"},"claim":"Allarity Therapeutics, Inc. entered into At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $947,000 (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, Allarity Therapeutics, Inc. (the “ Company ”), entered into an At-The-Market Issuance Sales Agreement (the “ Agreement ”) with Ascendiant Capital Markets, LLC (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-024156","anchor_url":"https://secwatch.observer/filing/0001213900-24-024156#claim-169cbd5660fb3c33ca74130400178659f67cf0a5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024024156/0001213900-24-024156-index.htm"},{"fact_type":"governance_change","fact_key":"87d77f480bde9e27343ea0f99aae6b9585a03a07","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-03-14","item_codes_triggered":["5.03"],"summary_text":"Filing of Seventh Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to reduce conversion price from $0.405 to $0.3501."},"claim":"Allarity Therapeutics, Inc.: Filing of Seventh Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to reduce conversion price from $0.405 to $0.3501 (effective 2024-03-14).","evidence_excerpt":"On March 14, 2024, we filed the Seventh Amendment to change the “Conversion Price” from $0.405 to $0.3501.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-022845","anchor_url":"https://secwatch.observer/filing/0001213900-24-022845#claim-87d77f480bde9e27343ea0f99aae6b9585a03a07","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024022845/0001213900-24-022845-index.htm"},{"fact_type":"debt_financing","fact_key":"684627407692e2cfaf368b33552fe4f8c3137bfa","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"counterparty":"3i, LP","effective_date":"2024-03-14","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"8% per annum","item_codes_triggered":["2.03"],"maturity_text":"March 14, 2025","principal_text":"$660,000"},"claim":"Allarity Therapeutics, Inc. incurred convertible notes of $660,000 with 3i, LP at 8% per annum maturing March 14, 2025.","evidence_excerpt":"On March 14, 2024 (the “Subsequent Closing”), we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $660,000 (the “Principal Amount”) due on March 14, 2025 (the “Note,”","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-022845","anchor_url":"https://secwatch.observer/filing/0001213900-24-022845#claim-684627407692e2cfaf368b33552fe4f8c3137bfa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024022845/0001213900-24-022845-index.htm"},{"fact_type":"material_agreement","fact_key":"541cf9c697bb4dd3ea533ce990507961cc8c3d7b","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement (Note)","agreement_type":"notes_offering","counterparty":"3i, LP","effective_date":"2024-03-14","item_codes_triggered":["1.01"],"value_text":"$660,000 senior convertible promissory note, 8% interest, conversion price $0.3501"},"claim":"Allarity Therapeutics, Inc. entered into Securities Purchase Agreement (Note) with 3i, LP valued at $660,000 senior convertible promissory note, 8% interest, conversion price $0.3501 (effective 2024-03-14).","evidence_excerpt":"Item 1.01 Entry into a Material Definitive Agreement. Subsequent Closing As previously disclosed, on January 18, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement, as amended by the First Amendment to Securities Purchase Agreement, dated as of January 25, 2024 (as so amended, the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser” and together with us, the “Parties”). On March 14, 2024 (the “Subsequent Closing”), we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $660,000 (the “Principal Amount”) due on March 14, 2025 (the “Note,” and together with the Notes issued on January 18, 2024 and February 13, 2024, and the Purchase Agreement, the “Transaction Documents”) for an aggregate purchase price of $600,000, representing an approximately 10% original issue discount (the “Transaction”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-022845","anchor_url":"https://secwatch.observer/filing/0001213900-24-022845#claim-541cf9c697bb4dd3ea533ce990507961cc8c3d7b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024022845/0001213900-24-022845-index.htm"},{"fact_type":"earnings_release","fact_key":"7eae35e68e3a84a28524f8cb3c6deac9404bbc2d","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$11.9 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-08","result_type":"reported_results","revenue_text":null},"claim":"Allarity Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $11.9 million.","evidence_excerpt":"Net loss was $11.9 million for 2023, compared to $16.1 million for 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-020882","anchor_url":"https://secwatch.observer/filing/0001213900-24-020882#claim-7eae35e68e3a84a28524f8cb3c6deac9404bbc2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024020882/0001213900-24-020882-index.htm"},{"fact_type":"executive_change","fact_key":"5b5b65c5a6","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-04T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-02-29","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Marie Foegh was terminated as Chief Medical Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On February 28, 2024, Allarity Therapeutics, Inc. (the “Company”) terminated the employment of Marie Foegh, M.D., the Company’s Chief Medical Officer. Ms. Foegh’s last day of employment was February 29, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-019540","anchor_url":"https://secwatch.observer/filing/0001213900-24-019540#claim-5b5b65c5a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024019540/0001213900-24-019540-index.htm"},{"fact_type":"material_agreement","fact_key":"5f769f6960ff7b37ed57593a743ef0ab49ad1da8","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-03-01T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Senior Convertible Notes","agreement_type":"notes_offering","counterparty":"3i, LP","effective_date":"2024-02-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. amended Amendment to Senior Convertible Notes with 3i, LP (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership, (the “Holder” and together with us, the “Parties”) entered into an Amendment to Senior Convertible Notes (the “Amendment”) to two senior convertible notes dated as of January 18, 2024 and February 13, 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-018789","anchor_url":"https://secwatch.observer/filing/0001213900-24-018789#claim-5f769f6960ff7b37ed57593a743ef0ab49ad1da8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024018789/0001213900-24-018789-index.htm"},{"fact_type":"governance_change","fact_key":"6777c0f7db7c31a634decb82f284fb03ca1ddf9a","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-02-13","item_codes_triggered":["5.03"],"summary_text":"Amended Series A Preferred Stock conversion price from $0.4476 to $0.405 via Sixth Certificate of Amendment"},"claim":"Allarity Therapeutics, Inc.: Amended Series A Preferred Stock conversion price from $0.4476 to $0.405 via Sixth Certificate of Amendment (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, we filed the Sixth Amendment to change the “Conversion Price” from $0.4476 to $0.405.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-013668","anchor_url":"https://secwatch.observer/filing/0001213900-24-013668#claim-6777c0f7db7c31a634decb82f284fb03ca1ddf9a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm"},{"fact_type":"debt_financing","fact_key":"93fd9ccf2b0774042a717e7670b3cab99d3e47f7","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"counterparty":"3i, LP","effective_date":"2024-02-13","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"8% per annum","item_codes_triggered":["2.03"],"maturity_text":"2025-02-13","principal_text":"$440,000"},"claim":"Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing 2025-02-13.","evidence_excerpt":"we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on February 13, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-013668","anchor_url":"https://secwatch.observer/filing/0001213900-24-013668#claim-93fd9ccf2b0774042a717e7670b3cab99d3e47f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm"},{"fact_type":"material_agreement","fact_key":"ff4735be549060d2645e20de96f4c5268fa6c480","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Limited Waiver Agreement and Second Convertible Promissory Note","agreement_type":"credit_facility","counterparty":"3i, LP","effective_date":"2024-02-13","item_codes_triggered":["1.01"],"value_text":"$440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share"},"claim":"Allarity Therapeutics, Inc. entered into Limited Waiver Agreement and Second Convertible Promissory Note with 3i, LP valued at $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024 (the “Second Closing”), the Parties entered into a Limited Waiver Agreement (the “Waiver Agreement”) and agreed that the Second Closing can be consummated prior to the 30 th calendar day following January 18, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-013668","anchor_url":"https://secwatch.observer/filing/0001213900-24-013668#claim-ff4735be549060d2645e20de96f4c5268fa6c480","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024013668/0001213900-24-013668-index.htm"},{"fact_type":"material_agreement","fact_key":"60badcc469615f6061d2177b40dc614205228504","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Agreement","agreement_type":"license","counterparty":"Novartis Pharma AG","effective_date":"2024-01-26","item_codes_triggered":["1.02"],"value_text":null},"claim":"Allarity Therapeutics, Inc. terminated Agreement with Novartis Pharma AG (effective 2024-01-26).","evidence_excerpt":"On January 26, 2024, we received written notice from Novartis indicating their decision to terminate the Agreement based on material breach for lack of financial payment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-009034","anchor_url":"https://secwatch.observer/filing/0001213900-24-009034#claim-60badcc469615f6061d2177b40dc614205228504","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm"},{"fact_type":"executive_change","fact_key":"4d2b3a32a1","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"for_cause_or_dispute","effective_date":"2024-01-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James G. Cullem resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On January 27, 2024, the Chairman of our Board of Directors (the “Board”), received email correspondence from Mr. James G. Cullem tendering his resignation (the “Resignation Email”) as a member of our Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-009034","anchor_url":"https://secwatch.observer/filing/0001213900-24-009034#claim-4d2b3a32a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024009034/0001213900-24-009034-index.htm"},{"fact_type":"material_agreement","fact_key":"9cd33aa2883311d7287166dde83a88f9f3d48f7f","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-01-25T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment","agreement_type":"equity_purchase","counterparty":"3i, LP","effective_date":"2024-01-25","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. amended Amendment with 3i, LP (effective 2024-01-25).","evidence_excerpt":"On January 25, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership (the “Purchaser”), executed an amendment (the “Amendment”) to that certain Securities Purchase Agreement dated as of January 18, 2024 (the “Original Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-006554","anchor_url":"https://secwatch.observer/filing/0001213900-24-006554#claim-9cd33aa2883311d7287166dde83a88f9f3d48f7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024006554/0001213900-24-006554-index.htm"},{"fact_type":"debt_financing","fact_key":"95c5e888bbdb93915532d095f8874452038335ba","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"counterparty":"3i, LP","effective_date":"2024-01-18","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"8% per annum","item_codes_triggered":["2.03"],"maturity_text":"January 18, 2025","principal_text":"$440,000"},"claim":"Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing January 18, 2025.","evidence_excerpt":"we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on January 18, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-004946","anchor_url":"https://secwatch.observer/filing/0001213900-24-004946#claim-95c5e888bbdb93915532d095f8874452038335ba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm"},{"fact_type":"material_agreement","fact_key":"5a9812dd514bcd4c2b19d85b0750ad181a3514c3","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"3i, LP","effective_date":"2024-01-18","item_codes_triggered":["1.01"],"value_text":"$440,000"},"claim":"Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with 3i, LP valued at $440,000 (effective 2024-01-18).","evidence_excerpt":"On January 18, 2024 (the “First Closing Date”), Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-004946","anchor_url":"https://secwatch.observer/filing/0001213900-24-004946#claim-5a9812dd514bcd4c2b19d85b0750ad181a3514c3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024004946/0001213900-24-004946-index.htm"},{"fact_type":"executive_change","fact_key":"e4b530f120","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-12-08","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Thomas Jensen was appointed as Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-23-094535","anchor_url":"https://secwatch.observer/filing/0001213900-23-094535#claim-e4b530f120","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm"},{"fact_type":"executive_change","fact_key":"879d5da2d8","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2023-12-08","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Thomas Jensen","successor_named":true},"claim":"James Cullem was terminated as Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-23-094535","anchor_url":"https://secwatch.observer/filing/0001213900-23-094535#claim-879d5da2d8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023094535/0001213900-23-094535-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"173512f712b9f172cb9cf6a0f3e73dd69ab5887f","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-11-17T23:59:59+00:00","payload":{"company_response":"will present views at panel hearing","compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":"2024-02-01","immediate_listing_effect":null,"minimum_requirement":"$2,500,000","notice_date":"2023-11-16","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":"($3,379,000)","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equity, as reported in its\nQuarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”), did not satisfy the continued listing\nrequirement under Listing Rule 5550(b)(1) for The Nasdaq Capital Market, which requires that a listed company’s stockholders’\nequity be at least $2.5 million. As reported on the Form 10-Q, the Company’s stockholders’ equity as of September 30, 2023\nwas ($3,379,000). Pursuant to the Staff letter , the Company is not eligible for a 180-calendar day","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-088375","anchor_url":"https://secwatch.observer/filing/0001213900-23-088375#claim-173512f712b9f172cb9cf6a0f3e73dd69ab5887f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"ebd0259c562165f2da6d3240ba408e649bad5304","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-11-17T23:59:59+00:00","payload":{"company_response":"appealed and requested hearing","compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":"2024-02-01","immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-10-27","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"October 27, 2023, we received a notification from Staff that it has determined that the bid price of our Common Stock has closed at less\nthan $1 per share over the previous 30 consecutive business days, and did not comply with Listing Rule 5550(a)(2). As a result, our Common\nStock will be delisted from The Nasdaq Capital Market. We have appealed such determination by requesting a hearing. The hearing has been\nscheduled for February 1, 2024 before a Nasdaq Hearing Panel (the “Panel Hearing”). On\nNovember 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equ","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-088375","anchor_url":"https://secwatch.observer/filing/0001213900-23-088375#claim-ebd0259c562165f2da6d3240ba408e649bad5304","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023088375/0001213900-23-088375-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"535f87b9c2cbe3a0b83a5c509ce4516ba6261c32","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-10-30T23:59:59+00:00","payload":{"company_response":"intends to appeal","compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":"2023-11-07","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-10-27","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)(iv)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).","evidence_excerpt":"October 27, 2023, we received\nnotification from the Nasdaq Listing Qualifications staff that it has determined that the bid price of our Common Stock has closed at\nless than $1 per share over the previous 30 consecutive business days, and, as a result, does not comply with Listing Rule 5550(a)(2)\n(the “Rule”). Further, the staff also noted that we effected an 1:35 reverse stock split on March 24, 2023, and an 1:40 reverse\nstock split on June 28, 2023. Because we effected one or more reverse stock splits over the prior two-year period with a cumulative ratio\nof 250 shares or more to one, we wil","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-081575","anchor_url":"https://secwatch.observer/filing/0001213900-23-081575#claim-535f87b9c2cbe3a0b83a5c509ce4516ba6261c32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023081575/0001213900-23-081575-index.htm"},{"fact_type":"governance_change","fact_key":"abcc07c56855694a4a8c0f80cfbfa92521e4d411","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-09-27T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-09-22","item_codes_triggered":["5.03"],"summary_text":"Fourth Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock filed to reduce the conversion price from $4.50 to $1.00"},"claim":"Allarity Therapeutics, Inc.: Fourth Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock filed to reduce the conversion price from $4.50 to $1.00 (effective 2023-09-22).","evidence_excerpt":"On September 22, 2023 the Company filed the Fourth Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-079918","anchor_url":"https://secwatch.observer/filing/0001213900-23-079918#claim-abcc07c56855694a4a8c0f80cfbfa92521e4d411","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023079918/0001213900-23-079918-index.htm"},{"fact_type":"executive_change","fact_key":"4883ea50c9","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-08-07","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert Oliver resigned as director at Allarity Therapeutics, Inc..","evidence_excerpt":"On August 7, 2023, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) received the resignation of Mr. Robert Oliver as director of the Company, including his position on each Board committee on which he was appointed to, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-065890","anchor_url":"https://secwatch.observer/filing/0001213900-23-065890#claim-4883ea50c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023065890/0001213900-23-065890-index.htm"},{"fact_type":"executive_change","fact_key":"c3ae1d89c8","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert Oliver was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class III Director: Mr. Robert Oliver, whose term will expire at the Company’s 2025 annual meeting of stockholders or until his respective successors are duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-060254","anchor_url":"https://secwatch.observer/filing/0001213900-23-060254#claim-c3ae1d89c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm"},{"fact_type":"executive_change","fact_key":"ec23854882","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Laura Benjamin was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class II Director: Dr. Laura Benjamin, whose term will expire at the Company’s 2024 annual meeting of stockholders or until her respective successors are duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-060254","anchor_url":"https://secwatch.observer/filing/0001213900-23-060254#claim-ec23854882","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm"},{"fact_type":"executive_change","fact_key":"1487745023","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joe Vazzano was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-060254","anchor_url":"https://secwatch.observer/filing/0001213900-23-060254#claim-1487745023","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm"},{"fact_type":"executive_change","fact_key":"b340578677","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-07-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Roth resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-060254","anchor_url":"https://secwatch.observer/filing/0001213900-23-060254#claim-b340578677","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023060254/0001213900-23-060254-index.htm"},{"fact_type":"governance_change","fact_key":"7e120d9c4462d8c07cffc6fb5533036ba0df6fc7","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-11T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-07-11","item_codes_triggered":["5.03"],"summary_text":"Reduced conversion price of Series A Convertible Preferred Stock from $8.00 to $4.50 via Third Certificate of Amendment to Amended and Restated Certificate of Designations"},"claim":"Allarity Therapeutics, Inc.: Reduced conversion price of Series A Convertible Preferred Stock from $8.00 to $4.50 via Third Certificate of Amendment to Amended and Restated Certificate of Designations (effective 2023-07-11).","evidence_excerpt":"On July 11, 2023, we filed a Third Amendment to change the “Conversion Price” from $8.00 to $4.50.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-056196","anchor_url":"https://secwatch.observer/filing/0001213900-23-056196#claim-7e120d9c4462d8c07cffc6fb5533036ba0df6fc7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm"},{"fact_type":"material_agreement","fact_key":"494b947130a2ab3ae6d81fbce6f37478912db0eb","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-11T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended and Restated Common Stock Purchase Warrant","agreement_type":"equity_purchase","counterparty":"the investors who acquired securities in the April Offering","effective_date":"2023-07-10","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. amended Amended and Restated Common Stock Purchase Warrant with the investors who acquired securities in the April Offering (effective 2023-07-10).","evidence_excerpt":"Concurrent with the close of the Offering, the Company entered into an Amended and Restated Common Stock Purchase Warrant to memorialize the repricing and the extension of termination date (“Amended and Restated Warrant”).","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001213900-23-056196","anchor_url":"https://secwatch.observer/filing/0001213900-23-056196#claim-494b947130a2ab3ae6d81fbce6f37478912db0eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm"},{"fact_type":"material_agreement","fact_key":"f0b75b907460ee03b1f4b31497694186d86d0e1d","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"A.G.P./Alliance Global Partners","effective_date":"2023-07-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-07-05).","evidence_excerpt":"Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-056196","anchor_url":"https://secwatch.observer/filing/0001213900-23-056196#claim-f0b75b907460ee03b1f4b31497694186d86d0e1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm"},{"fact_type":"material_agreement","fact_key":"069da384f7df45f43d2672e82e2814af5f820950","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-07-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"the Purchasers","effective_date":"2023-07-05","item_codes_triggered":["1.01"],"value_text":"approximately $11 million"},"claim":"Allarity Therapeutics, Inc. entered into Purchase Agreement with the Purchasers valued at approximately $11 million (effective 2023-07-05).","evidence_excerpt":"On July 5, 2023, Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) agreed to sell in a public offering an aggregate of 357,223 shares of Common Stock of the Company (the “Shares”), pre-funded warrants to purchase up to 2,087,222 shares of Common Stock (the “Pre-Funded Warrants”), and common warrants to purchase up to 2,444,445 shares of Common Stock (the “Common Warrants” together with the Shares, the Pre-Funded Warrants and Common Stock issuable upon exercise of the Common Warrants and the Pre-Funded Warrants, collectively, the “Securities”), at an effective combined purchase price of $4.50 per share and related Common Warrant (the “Purchase Price”), for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and offering expenses payable by the Company (the “Offering”). The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto (each, a “Pu","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-056196","anchor_url":"https://secwatch.observer/filing/0001213900-23-056196#claim-069da384f7df45f43d2672e82e2814af5f820950","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023056196/0001213900-23-056196-index.htm"},{"fact_type":"debt_financing","fact_key":"bbe180a851bb3bdd3615bd5234aa28255a8e7fd9","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-30T23:59:59+00:00","payload":{"counterparty":"3i LP","effective_date":"2023-06-30","event":"incurrence","instrument_type":"loan","interest_rate_text":"5% per annum","item_codes_triggered":["2.03"],"maturity_text":"July 31, 2023","principal_text":"$350,000"},"claim":"Allarity Therapeutics, Inc. incurred loan of $350,000 with 3i LP at 5% per annum maturing July 31, 2023.","evidence_excerpt":"Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000 to be issued at closing (the “Note”). The closing for the Note occurred on June 30, 2023 and the purchase price for the Note was paid in cash (“Closing”). The Note matures on July 31, 2023, carries an interest rate of at 5% per annum","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-053500","anchor_url":"https://secwatch.observer/filing/0001213900-23-053500#claim-bbe180a851bb3bdd3615bd5234aa28255a8e7fd9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm"},{"fact_type":"material_agreement","fact_key":"2e2b135dde34f15bff4dab0180e080c627fcb160","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Secured Note Purchase Agreement","agreement_type":"notes_offering","counterparty":"3i LP","effective_date":"2023-06-29","item_codes_triggered":["1.01"],"value_text":"$350,000"},"claim":"Allarity Therapeutics, Inc. entered into Secured Note Purchase Agreement with 3i LP valued at $350,000 (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Allarity Therapeutics, Inc. (the “Company”) entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP, the sole holder of the Company’s outstanding shares of Series A Preferred Stock. Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001213900-23-053500","anchor_url":"https://secwatch.observer/filing/0001213900-23-053500#claim-2e2b135dde34f15bff4dab0180e080c627fcb160","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm"},{"fact_type":"governance_change","fact_key":"0f414e7eb0e45a5f9b4c1d24e28993244ae8d7bf","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-28T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-06-28","item_codes_triggered":["5.03"],"summary_text":"Filed Fourth Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock."},"claim":"Allarity Therapeutics, Inc.: Filed Fourth Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock (effective 2023-06-28).","evidence_excerpt":"On June 28, 2023, upon receipt of the required stockholder approval, Allarity Therapeutics, Inc. (the “Company”) filed a Fourth Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on June 28, 2023 (the “Reverse Stock Split”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-052454","anchor_url":"https://secwatch.observer/filing/0001213900-23-052454#claim-0f414e7eb0e45a5f9b4c1d24e28993244ae8d7bf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023052454/0001213900-23-052454-index.htm"},{"fact_type":"shareholder_vote","fact_key":"24d25054ec266a6cb1e50131534daa1a05a9cd47","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-23T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-23","outcome":"passed","proposal_text":"To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"103,974","votes_against":"4,899,237","votes_for":"27,928,931","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal at the 2023-06-23 meeting.","evidence_excerpt":"Proposal 2 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (“Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 27,928,931 4,899,237 103,974 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-051421","anchor_url":"https://secwatch.observer/filing/0001213900-23-051421#claim-24d25054ec266a6cb1e50131534daa1a05a9cd47","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023051421/0001213900-23-051421-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4edb89f2e79fea8d0cf3380c97aa1f0208dfe5a1","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-23T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-23","outcome":"passed","proposal_text":"To approve an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-15 and 1-for-50","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"40,629","votes_against":"7,906,612","votes_for":"24,984,901","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To approve an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-15 and 1-for-50 at the 2023-06-23 meeting.","evidence_excerpt":"Proposal 1 : To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix A, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.0001 per share, at a ratio between 1-for-15 and 1-for-50 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board, subject to the consent of the holder of Series A Preferred Stock (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 24,984,901 7,906,612 40,629 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-051421","anchor_url":"https://secwatch.observer/filing/0001213900-23-051421#claim-4edb89f2e79fea8d0cf3380c97aa1f0208dfe5a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023051421/0001213900-23-051421-index.htm"},{"fact_type":"governance_change","fact_key":"0d9abf63d686289e2796348056bf77cd91db738e","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-01T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-05-30","item_codes_triggered":["5.03"],"summary_text":"Amendment to Certificate of Designations to modify voting rights of Series A Preferred Stock"},"claim":"Allarity Therapeutics, Inc.: Amendment to Certificate of Designations to modify voting rights of Series A Preferred Stock (effective 2023-05-30).","evidence_excerpt":"On May 30, 2023, the Company filed a First Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock (the “Amended COD”) to amend and restate the voting provisions of the Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock, which was originally filed with the Secretary of State of the State of Delaware on April 21, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-045091","anchor_url":"https://secwatch.observer/filing/0001213900-23-045091#claim-0d9abf63d686289e2796348056bf77cd91db738e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023045091/0001213900-23-045091-index.htm"},{"fact_type":"material_agreement","fact_key":"617317989192dd55ad881d000fee2838b71a546b","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-01T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Modification and Exchange Agreement","agreement_type":"other","counterparty":"3i, LP","effective_date":"2023-04-20","item_codes_triggered":["1.01"],"value_text":"Correction of share count from 4,027 to 5,577 shares of Series A Preferred Stock"},"claim":"Allarity Therapeutics, Inc. amended Amendment to Modification and Exchange Agreement with 3i, LP valued at Correction of share count from 4,027 to 5,577 shares of Series A Preferred Stock (effective 2023-04-20).","evidence_excerpt":"On May 26, 2023, the Company and 3i entered into an Amendment to Modification and Exchange Agreement (the “Amendment”), effective as of April 20, 2023, to correct an error relating to the Original Shares in the Original Agreement. Due to an error in not taking into account the proposed redemption of 1,550 share of Series A Preferred Stock, the Original Agreement incorrectly referenced “4,027” shares of Series A Preferred Stock instead of “ 5,577.” Accordingly, the Amendment corrects such error and memorializes that the parties originally agreed to exchange the Series C Shares for 5,577 shares of Series A Preferred Stock.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-045091","anchor_url":"https://secwatch.observer/filing/0001213900-23-045091#claim-617317989192dd55ad881d000fee2838b71a546b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023045091/0001213900-23-045091-index.htm"},{"fact_type":"material_agreement","fact_key":"5cc4d7a9bcd3334b06e370c87c1ee371b609fd13","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-01T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Fourth Amendment to the Exclusive License Agreement","agreement_type":"license","counterparty":"Eisai, Inc.","effective_date":"2023-05-16","item_codes_triggered":["1.01"],"value_text":"Periodic payments: $100,000 paid; $50,000 within 10 days; $100,000 upon capital raise; $850,000 by M"},"claim":"Allarity Therapeutics, Inc. amended Fourth Amendment to the Exclusive License Agreement with Eisai, Inc. valued at Periodic payments: $100,000 paid; $50,000 within 10 days; $100,000 upon capital raise; $850,000 by M (effective 2023-05-16).","evidence_excerpt":"On May 26, 2023, the Company and Eisai entered into a Fourth Amendment to the Exclusive License Agreement with an effective date of May 16, 2023 (the “Eisai Amendment”), to postpone the extension payment, restructure the payment schedule and extend the deadline to complete enrollment in a further Phase 1b or Phase 2 Clinical Trial for the Stenoparib (the “Product”). Under the Eisai Amendment, the Company agreed to pay Eisai in periodic payments as follows: (i) one hundred thousand dollars ($100,000) which has been paid; (ii) fifty thousand dollars ($50,000) within ten (10) days of execution of the fourth amendment; (iii) one hundred thousand dollars ($100,000) upon completion of a capital raise; and (iv) eight hundred and fifty thousand dollars ($850,000) on or before March 1, 2024. The Company will have until April 1, 2024, to complete enrollment in a further Phase 1b or Phase 2 Clinical Trial of the Product. If the Company has not achieved successful completion of a further Phase 1b","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-045091","anchor_url":"https://secwatch.observer/filing/0001213900-23-045091#claim-5cc4d7a9bcd3334b06e370c87c1ee371b609fd13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023045091/0001213900-23-045091-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"fd658f56d091eb671037cff4e767a9c9fa8d2852","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-05-26T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":"2023-05-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":"2023-05-18","immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-05-23","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"May 23, 2023, the Company\nreceived a letter from the Nasdaq Regulation staff (“Letter”) stating that the Company did not regain compliance under the\nRule by May 22, 2023, and such non-compliance will serve as an additional basis for delisting of the Company’s common stock from\nThe Nasdaq Stock Market. Further, the Nasdaq Hearings Panel, which on May 18, 2023, heard the Company’s appeal for non-compliance with the stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5450(b)(1)(A), will consider the Letter in their decision regarding the Company’s\ncontinued listing on The Nasdaq","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-043580","anchor_url":"https://secwatch.observer/filing/0001213900-23-043580#claim-fd658f56d091eb671037cff4e767a9c9fa8d2852","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023043580/0001213900-23-043580-index.htm"},{"fact_type":"governance_change","fact_key":"a02a21f07c395e8e79b0d853d9988d5e85b67919","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-25T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-04-21","item_codes_triggered":["5.03"],"summary_text":"Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to eliminate redemption right and dividend and adjust conversion price."},"claim":"Allarity Therapeutics, Inc.: Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to eliminate redemption right and dividend and adjust conversion price (effective 2023-04-21).","evidence_excerpt":"On April 21, 2023, in connection with the transactions contemplated under the Exchange Agreement, the Company filed an Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “Amended and Restated Series A COD”) with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-032547","anchor_url":"https://secwatch.observer/filing/0001213900-23-032547#claim-a02a21f07c395e8e79b0d853d9988d5e85b67919","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm"},{"fact_type":"material_agreement","fact_key":"5bd891c641d6632880379e4f00e00e0135c30a73","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-25T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Modification and Exchange Agreement","agreement_type":"other","counterparty":"3i, LP","effective_date":"2023-04-20","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. entered into Modification and Exchange Agreement with 3i, LP (effective 2023-04-20).","evidence_excerpt":"On April 20, 2023, the Company entered into a certain Modification and Exchange Agreement (the “Exchange Agreement”) with 3i","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-032547","anchor_url":"https://secwatch.observer/filing/0001213900-23-032547#claim-5bd891c641d6632880379e4f00e00e0135c30a73","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm"},{"fact_type":"material_agreement","fact_key":"819d76f24b0b28b3974a75be951ef53a0e892b4e","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-25T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"A.G.P./Alliance Global Partners","effective_date":"2023-04-19","item_codes_triggered":["1.01"],"value_text":"a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre"},"claim":"Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre (effective 2023-04-19).","evidence_excerpt":"Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-032547","anchor_url":"https://secwatch.observer/filing/0001213900-23-032547#claim-819d76f24b0b28b3974a75be951ef53a0e892b4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm"},{"fact_type":"material_agreement","fact_key":"8f43e7fa85556254c0e20ee847c2e72f3eec6e2c","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-25T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain purchasers","effective_date":"2023-04-19","item_codes_triggered":["1.01"],"value_text":"aggregate gross proceeds of approximately $7.5 million"},"claim":"Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at aggregate gross proceeds of approximately $7.5 million (effective 2023-04-19).","evidence_excerpt":"The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-032547","anchor_url":"https://secwatch.observer/filing/0001213900-23-032547#claim-8f43e7fa85556254c0e20ee847c2e72f3eec6e2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023032547/0001213900-23-032547-index.htm"},{"fact_type":"debt_financing","fact_key":"4ad69a141a1f4f4d4663f66ac42cc8e20ad0a660","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","payload":{"counterparty":"3i, LP","effective_date":"2023-04-11","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"5% per annum","item_codes_triggered":["2.03"],"maturity_text":"January 1, 2024","principal_text":"$350,000"},"claim":"Allarity Therapeutics, Inc. incurred convertible notes of $350,000 with 3i, LP at 5% per annum maturing January 1, 2024.","evidence_excerpt":"On April 11, 2023, 3i purchased an additional note for an aggregate amount of $350,000, which purchase price was paid for in cash. Each note issued under the Purchase Agreement matures on January 1, 2024, carries an interest rate of at 5% per annum, and is secured by all of the Company’s assets pursuant to a security agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-029177","anchor_url":"https://secwatch.observer/filing/0001213900-23-029177#claim-4ad69a141a1f4f4d4663f66ac42cc8e20ad0a660","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm"},{"fact_type":"material_agreement","fact_key":"c7dfa9a362b08c0425b0fd20c2d9b1d8a7a2cb83","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"First Amendment to the Secured Note Purchase Agreement","agreement_type":"notes_offering","counterparty":"3i, LP","effective_date":"2023-04-10","item_codes_triggered":["1.01"],"value_text":"aggregate principal amount of $2,666,640"},"claim":"Allarity Therapeutics, Inc. amended First Amendment to the Secured Note Purchase Agreement with 3i, LP valued at aggregate principal amount of $2,666,640 (effective 2023-04-10).","evidence_excerpt":"Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) entered into a First Amendment to the Secured Note Purchase Agreement dated April 10, 2023 (the “First Amendment”) with 3i, LP (“3i”), the sole holder of our Series A Convertible Preferred Stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-029177","anchor_url":"https://secwatch.observer/filing/0001213900-23-029177#claim-c7dfa9a362b08c0425b0fd20c2d9b1d8a7a2cb83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"55a3cb936a59a25b377bc086f22c5a39f8c4426a","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-04-12T23:59:59+00:00","payload":{"company_response":"Company intends to appeal","compliance_status":"delisting_pending","cure_deadline":"2023-04-10","deficiency_type":"stockholders_equity","delisting_effective_date":"2023-04-20","exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$10.0 million stockholders' equity","notice_date":"2023-04-11","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":"$8.0 million (as of June 30, 2022)","rule_numbers":["5450(b)(1)(A)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).","evidence_excerpt":"April 11, 2023, we received\nnotification from the Nasdaq Listing Qualifications staff that it has determined that the Company did not meet the terms of the extension.\nSpecifically, the Company did not complete its proposed transactions and was unable to file a Form 8-K by the April 10, 2023 deadline,\nevidencing compliance with the Rule. As a result, the Company’s securities will be delisted from The Nasdaq Global Market. In that\nregard, unless the Company requests an appeal of such determination, trading of the Company’s Common Stock will be suspended at\nthe opening of business on April 20, 20","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-029177","anchor_url":"https://secwatch.observer/filing/0001213900-23-029177#claim-55a3cb936a59a25b377bc086f22c5a39f8c4426a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023029177/0001213900-23-029177-index.htm"},{"fact_type":"governance_change","fact_key":"06a0ecec3e0254fdfa7a6d8fdb7df7ad75dbe001","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-03-24T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-03-24","item_codes_triggered":["5.03"],"summary_text":"Effected a 1-for-35 reverse stock split of common stock via amendment to Certificate of Incorporation"},"claim":"Allarity Therapeutics, Inc.: Effected a 1-for-35 reverse stock split of common stock via amendment to Certificate of Incorporation (effective 2023-03-24).","evidence_excerpt":"On March 23, 2023, the Company filed a Third Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-35 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on March 24, 2023 (the “Reverse Stock Split”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-022572","anchor_url":"https://secwatch.observer/filing/0001213900-23-022572#claim-06a0ecec3e0254fdfa7a6d8fdb7df7ad75dbe001","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023022572/0001213900-23-022572-index.htm"},{"fact_type":"governance_change","fact_key":"cf08108e7cedb91713a5a69f2db00813b06a8998","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-03-20","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares from 30,500,000 to 750,500,000 and common stock from 30,000,000 to 750,000,000."},"claim":"Allarity Therapeutics, Inc.: Increased authorized shares from 30,500,000 to 750,500,000 and common stock from 30,000,000 to 750,000,000 (effective 2023-03-20).","evidence_excerpt":"an amendment to Allarity Therapeutics, Inc.’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of shares of common stock (the “Common Stock”) from 30,000,000 to 750,000,000 (the “Share Increase”) was approved","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-021463","anchor_url":"https://secwatch.observer/filing/0001213900-23-021463#claim-cf08108e7cedb91713a5a69f2db00813b06a8998","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm"},{"fact_type":"shareholder_vote","fact_key":"97bfaa1415b386a3748d23c457c5da580b2989c5","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-20","outcome":"passed","proposal_text":"Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-20 and 1-for-35, at the discretion of the Board","proposal_type":"reverse_split","results":[{"broker_non_votes":"-","subject":null,"votes_abstain":"18,333","votes_against":"361,101","votes_for":"34,308,947","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-20 and 1-for-35, at the discretion of the Board at the 2023-03-20 meeting.","evidence_excerpt":"Proposal 2: To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-20 and 1-for-35 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 34,308,947 361,101 18,333 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-021463","anchor_url":"https://secwatch.observer/filing/0001213900-23-021463#claim-97bfaa1415b386a3748d23c457c5da580b2989c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm"},{"fact_type":"shareholder_vote","fact_key":"322f255d3ffb2d971501fc5b93b20a9c684441e2","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-03-20","outcome":"passed","proposal_text":"Approve amendment to Certificate of Incorporation to increase authorized shares from 30,500,000 to 750,500,000 and Common Stock from 30,000,000 to 750,000,000","proposal_type":"charter_amendment","results":[{"broker_non_votes":"-","subject":null,"votes_abstain":"11,500","votes_against":"410,898","votes_for":"34,265,983","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to increase authorized shares from 30,500,000 to 750,500,000 and Common Stock from 30,000,000 to 750,000,000 at the 2023-03-20 meeting.","evidence_excerpt":"Proposal 1: To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of our Common Stock from 30,000,000 to 750,000,000, in substantially the form attached to the Proxy Statement as Appendix A (the “Share Increase Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 34,265,983 410,898 11,500 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-021463","anchor_url":"https://secwatch.observer/filing/0001213900-23-021463#claim-322f255d3ffb2d971501fc5b93b20a9c684441e2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023021463/0001213900-23-021463-index.htm"},{"fact_type":"governance_change","fact_key":"275438e4d99e8a1ba4ede587ddc36a1410bcb3e5","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-02-28","item_codes_triggered":["5.03"],"summary_text":"Filed certificate of amendment to Series C COD to clarify conversion price and floor price"},"claim":"Allarity Therapeutics, Inc.: Filed certificate of amendment to Series C COD to clarify conversion price and floor price (effective 2023-02-28).","evidence_excerpt":"On February 28, 2023, the Company filed a certificate of amendment to the Series C COD (the “COD Amendment”) to clarify the terms of conversion price and floor price based on definitions provided in the Series C COD","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-015550","anchor_url":"https://secwatch.observer/filing/0001213900-23-015550#claim-275438e4d99e8a1ba4ede587ddc36a1410bcb3e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm"},{"fact_type":"governance_change","fact_key":"0de9986950c520aacaa3f473b82616a7df99764d","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-02-24","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designation of Series C Preferred Stock"},"claim":"Allarity Therapeutics, Inc.: Filed Certificate of Designation of Series C Preferred Stock (effective 2023-02-24).","evidence_excerpt":"Pursuant to the terms of the SPA, on February 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock (the “Series C COD”) with the Delaware Secretary of State designating 50,000 shares of its authorized and unissued preferred stock as Series C Preferred Stock with a stated value of $27.00 per share (the “Stated Value”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-015550","anchor_url":"https://secwatch.observer/filing/0001213900-23-015550#claim-0de9986950c520aacaa3f473b82616a7df99764d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023015550/0001213900-23-015550-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"d5dfff444f9496c706d82af89180764179e48551","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-10T23:59:59+00:00","payload":{"company_response":"seeking to appoint a new independent director","compliance_status":"deficient","cure_deadline":null,"deficiency_type":"audit_committee","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2023-02-08","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5605(b)(1)(A)","5605(c)(4)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(b)(1)(A), 5605(c)(4)).","evidence_excerpt":"February 8, 2023, Allarity\nTherapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that due to the resignation of Soren G. Jensen from the Company’s board and audit committee, effective on\nFebruary 4, 2023, the Company no longer complies with Nasdaq’s independent director and audit committee requirements as set forth\nin Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) which requires a majority of the board of directors to be comprised of independent\ndirectors and an audit committee of at least three independent dire","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-010353","anchor_url":"https://secwatch.observer/filing/0001213900-23-010353#claim-d5dfff444f9496c706d82af89180764179e48551","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023010353/0001213900-23-010353-index.htm"},{"fact_type":"shareholder_vote","fact_key":"80f2cfc7f2629265457644179a1879630cb412b6","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"passed","proposal_text":"To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Share Increase Proposal or the Reverse Stock Split Proposal (\"Adjournment Proposal\").","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"800","votes_against":"9,853,440","votes_for":"14,563,755","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Share Increase Proposal or the Reverse Stock Split Proposal (\"Adjournment Proposal\"). at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 9 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Share Increase Proposal or the Reverse Stock Split Proposal (“Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 14,563,755 9,853,440 800 -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-80f2cfc7f2629265457644179a1879630cb412b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5126f57429145d8525a1b0c8f8364af1a5ed69ae","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"passed","proposal_text":"To approve the issuance of Common Stock in connection with entering into a proposed equity line of credit at prices below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635.","proposal_type":"other","results":[{"broker_non_votes":"203,657","subject":null,"votes_abstain":"644","votes_against":"1,287,412","votes_for":"1,809,021","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To approve the issuance of Common Stock in connection with entering into a proposed equity line of credit at prices below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635. at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 8 : To approve the issuance of Common Stock in connection with entering into a proposed equity line of credit at prices below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635. Votes For Votes Against Abstentions Broker Non-Votes 1,809,021 1,287,412 644 203,657","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-5126f57429145d8525a1b0c8f8364af1a5ed69ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e8e9ceca3bc596f5cd08657f7cc31ed92683d0a0","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"unknown","proposal_text":"To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers.","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":null,"subject":"One Year","votes_abstain":null,"votes_against":null,"votes_for":"1,271,246","votes_withheld":null},{"broker_non_votes":null,"subject":"Two Years","votes_abstain":null,"votes_against":null,"votes_for":"1,844","votes_withheld":null},{"broker_non_votes":null,"subject":"Three Years","votes_abstain":null,"votes_against":null,"votes_for":"1,819,787","votes_withheld":null},{"broker_non_votes":null,"subject":"Abstentions","votes_abstain":null,"votes_against":null,"votes_for":"4,200","votes_withheld":null},{"broker_non_votes":null,"subject":"Broker Non-Votes","votes_abstain":null,"votes_against":null,"votes_for":"203,657","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders voted on To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers. at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 7 : To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers. One Year Two Years Three Years Abstentions Broker Non-Votes 1,271,246 1,844 1,819,787 4,200 203,657","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-e8e9ceca3bc596f5cd08657f7cc31ed92683d0a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6de1cc8958b8a315f777d6f80788b0d6afbd3d5b","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"passed","proposal_text":"To approve, on an advisory basis, the compensation of our named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"203,657","subject":null,"votes_abstain":"2,400","votes_against":"1,226,875","votes_for":"1,867,802","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of our named executive officers at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 6 : To approve, on an advisory basis, the compensation of our named executive officers Votes For Votes Against Abstentions Broker Non-Votes 1,867,802 1,226,875 2,400 203,657","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-6de1cc8958b8a315f777d6f80788b0d6afbd3d5b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"48dff3dad9899c13b8ea5c3613edc6a8f2411582","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"failed","proposal_text":"To approve the issuance of common stock at a price below the minimum price and in a number that will exceed 20% of our outstanding shares of common stock in accordance with Nasdaq Rule 5635(d) in connection with the shares of common stock that may be issuable upon conversion of shares of Series A Pr","proposal_type":"other","results":[{"broker_non_votes":"203,657","subject":null,"votes_abstain":null,"votes_against":"1,233,836","votes_for":"198,885","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders rejected To approve the issuance of common stock at a price below the minimum price and in a number that will exceed 20% of our outstanding shares of common stock in accordance with Nasdaq Rule 5635(d) in connection with the shares of common stock that may be issuable upon conversion of shares of Series A Pr at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 5 : To approve the issuance of common stock at a price below the minimum price and in a number that will exceed 20% of our outstanding shares of common stock in accordance with Nasdaq Rule 5635(d) in connection with the shares of common stock that may be issuable upon conversion of shares of Series A Preferred Stock pursuant to an amendment to our Certificate of Designations of Series A Convertible Preferred Stock, as amended, to decrease the conversion price from $9.9061 to $2.00 and the floor price from $1.98 to $0.10, which conversion and floor prices may be further adjusted by the Board subject to the listing requirements of the Nasdaq Stock Market (the “Series A Conversion Nasdaq Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 198,885 1,233,836 - 203,657 1","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-48dff3dad9899c13b8ea5c3613edc6a8f2411582","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1b99e2f2b353efa6bc0142a2b38bd86d5096c31c","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"failed","proposal_text":"To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the \"Board\"), effect a reverse stock split with respect to the Company’s issued and outsta","proposal_type":"reverse_split","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":null,"votes_against":"9,327,256","votes_for":"15,095,859","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders rejected To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the \"Board\"), effect a reverse stock split with respect to the Company’s issued and outsta at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 4 : To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.0001 per share, at a ratio between 1-for-2 and 1-for-10 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 15,095,859 9,327,256 - -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-1b99e2f2b353efa6bc0142a2b38bd86d5096c31c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f3572da36c2188ef0401877ac0528cd33d9b2d90","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"failed","proposal_text":"To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 150,500,000, and to increase the number of our common stock from 30,000,000 to 150,000,000, in substantially the form attached to the Proxy Statement as Appendix A","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":null,"votes_against":"9,797,600","votes_for":"14,625,515","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders rejected To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 150,500,000, and to increase the number of our common stock from 30,000,000 to 150,000,000, in substantially the form attached to the Proxy Statement as Appendix A at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 3 : To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 150,500,000, and to increase the number of our common stock from 30,000,000 to 150,000,000, in substantially the form attached to the Proxy Statement as Appendix A (the “Share Increase Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 14,625,515 9,797,600 - -","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-f3572da36c2188ef0401877ac0528cd33d9b2d90","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f29fedbeb1ca4eb1c6deb6e14d314681029705f0","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"passed","proposal_text":"To approve the issuance of Common Stock in one or more non-public offerings at a price below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635(d).","proposal_type":"other","results":[{"broker_non_votes":"203,657","subject":null,"votes_abstain":null,"votes_against":"1,282,379","votes_for":"1,814,698","votes_withheld":null}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To approve the issuance of Common Stock in one or more non-public offerings at a price below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635(d). at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 2 : To approve the issuance of Common Stock in one or more non-public offerings at a price below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635(d). Votes For Votes Against Abstentions Broker Non-Votes 1,814,698 1,282,379 - 203,657","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-f29fedbeb1ca4eb1c6deb6e14d314681029705f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a546f8f94e3f95107b9060e4d9cd13745eaa116b","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-02-03","outcome":"passed","proposal_text":"To elect two (2) Class I directors, Soren G. Jensen and Thomas Jensen, to serve until the 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":"203,657","subject":"Soren G. Jensen","votes_abstain":null,"votes_against":null,"votes_for":"2,934,725","votes_withheld":"162,352"},{"broker_non_votes":"203,657","subject":"Thomas Jensen","votes_abstain":null,"votes_against":null,"votes_for":"3,067,389","votes_withheld":"29,688"}]},"claim":"Allarity Therapeutics, Inc. shareholders approved To elect two (2) Class I directors, Soren G. Jensen and Thomas Jensen, to serve until the 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified. at the 2023-02-03 meeting.","evidence_excerpt":"Proposal 1 : To elect two (2) Class I directors, Soren G. Jensen and Thomas Jensen, to serve until the 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Soren G. Jensen 2,934,725 162,352 203,657 Thomas Jensen 3,067,389 29,688 203,657","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-a546f8f94e3f95107b9060e4d9cd13745eaa116b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"b160a5064e810df6a054dad9b3766dbdb57c8f96","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-02-06T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"board_independence","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-02-05","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5605(b)","5605(c)(2)","5605(b)(1)(A)","5605(c)(4)","5606(b)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b), 5605(c)(2), 5605(b)(1)(A), 5605(c)(4), 5606(b)).","evidence_excerpt":"February 5, 2023, the Company provided notice to Nasdaq that\nas a result of Mr. Jensen’s resignation, there are only two independent directors of the Company’s board and audit committee.\nUnder Nasdaq Listing Rule 5605(b), a majority of the board directors must be comprised of independent directors. Under Nasdaq Listing\nRule 5605(c)(2), the Company must have an audit committee of three members meeting the criteria of such rule. With Mr. Jensen’s\nresignation, the Company’s current board consists of four members, two of whom are independent and the Company’s audit committee\nconsist of two members","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-008236","anchor_url":"https://secwatch.observer/filing/0001213900-23-008236#claim-b160a5064e810df6a054dad9b3766dbdb57c8f96","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023008236/0001213900-23-008236-index.htm"},{"fact_type":"material_agreement","fact_key":"16a01112788f1d9aa4f77d2010e9c2eab3b59eb7","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Letter Agreement","agreement_type":"other","counterparty":"3i, LP","effective_date":"2023-01-23","item_codes_triggered":["1.01"],"value_text":"Amendment to extend conversion price modification until terminated by Company and 3i"},"claim":"Allarity Therapeutics, Inc. amended Letter Agreement with 3i, LP valued at Amendment to extend conversion price modification until terminated by Company and 3i (effective 2023-01-23).","evidence_excerpt":"On January 23, 2023, the Company and 3i amended the Letter Agreement to provide the term Conversion Price will be in effect until terminated by the Company and 3i.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-004263","anchor_url":"https://secwatch.observer/filing/0001213900-23-004263#claim-16a01112788f1d9aa4f77d2010e9c2eab3b59eb7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004263/0001213900-23-004263-index.htm"},{"fact_type":"executive_change","fact_key":"f88085328d","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-01-20T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Soren G. Jensen resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On January 19, 2023, Mr. Soren G. Jensen gave notice that he will resign as a director, to be effective as of February 4, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-004105","anchor_url":"https://secwatch.observer/filing/0001213900-23-004105#claim-f88085328d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004105/0001213900-23-004105-index.htm"},{"fact_type":"executive_change","fact_key":"5c177db02a","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-01-20T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-01-19","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gail Maderis resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On January 19, 2023, Mr. Duncan Moore and Ms. Gail Maderis resigned as directors of Allarity Therapeutics, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-004105","anchor_url":"https://secwatch.observer/filing/0001213900-23-004105#claim-5c177db02a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004105/0001213900-23-004105-index.htm"},{"fact_type":"executive_change","fact_key":"eb6e9094b0","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-01-20T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-01-19","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Duncan Moore resigned as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"On January 19, 2023, Mr. Duncan Moore and Ms. Gail Maderis resigned as directors of Allarity Therapeutics, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-004105","anchor_url":"https://secwatch.observer/filing/0001213900-23-004105#claim-eb6e9094b0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023004105/0001213900-23-004105-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"b9cb1023ae8b53877302bb999b9077a54271a6cc","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-12-23T23:59:59+00:00","payload":{"company_response":"submitted plan to regain compliance, including raising additional capital and seeking to phase down to Nasdaq Capital Market","compliance_status":"extension_granted","cure_deadline":"2023-04-10","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2022-12-21","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(b)(1)(A)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5450(b)(1)(A)).","evidence_excerpt":"December 21, 2022,\nthe Company received notification from the Nasdaq staff that they have granted the Company an extension of time until April 10, 2023,\nto regain and evidence compliance with the Rule. No assurance can be given\nthat the Company will be able to regain compliance with the Rule by April 10, 2023, as well as meet other notifications of deficiency\nsubject to previous disclosure on Form 8-K (See Form 8-Ks filed with the SEC on November 25, and December 20, 2022). 1 SIGNATURES Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this rep","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-082358","anchor_url":"https://secwatch.observer/filing/0001213900-22-082358#claim-b9cb1023ae8b53877302bb999b9077a54271a6cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022082358/0001213900-22-082358-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4056e8fba2b39e4be9cc36407051e68f0bed4328","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-12-21T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-06-19","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$5,000,000 market value of publicly held shares","notice_date":"2022-12-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"minimum Market Value of Publicly Held Shares of $5,000,000 under Listing Rule 5450(b)(1)(C) and compliance period provided under Listing Rule 5810(c)(3)(D)","reported_value":null,"rule_numbers":["5450(b)(1)(C)","5810(c)(3)(D)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).","evidence_excerpt":"December 20, 2022, the Company\nreceived a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”)\nindicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000\nunder the Nasdaq Listing Rules (the “Listing Rules”). Based on the Company’s MVPHS for the last thirty-one (31) consecutive\nbusiness days from November 4, 2022 to December 19, 2022, the Company no longer meets the minimum MVPHS requirement set forth in Listing\nRule 5450(b)(1)(C). The Notice is only a notificatio","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-081611","anchor_url":"https://secwatch.observer/filing/0001213900-22-081611#claim-4056e8fba2b39e4be9cc36407051e68f0bed4328","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022081611/0001213900-22-081611-index.htm"},{"fact_type":"material_agreement","fact_key":"af41960c8a38129c17286f84f81ecc827ee8ca5d","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","payload":{"action":"amendment","agreement_name":null,"agreement_type":"equity_purchase","counterparty":"3i, LP","effective_date":"2022-12-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. amended a equity purchase with 3i, LP (effective 2022-12-09).","evidence_excerpt":"On December 9, 2022, the Company and 3i, LP (“3i”), the holder of outstanding shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) entered into a letter agreement which provided that pursuant to Section 8(g) of the Certificate of Designations for the Series A Preferred Stock, the parties agreed that the Conversion Price (as defined in such Certificate of Designations”) was modified to mean the lower of: (i) the Closing Sale Price (as defined in the Certificate of Designations) on the trading date immediately preceding the Conversion Date (as defined in the Certificate of Designations and (ii) the average Closing Sale Price of the common stock for the five trading days immediately preceding the Conversion Date, for the Trading Days (as defined in the Certificate of Designations) through and inclusive of January 19, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-078885","anchor_url":"https://secwatch.observer/filing/0001213900-22-078885#claim-af41960c8a38129c17286f84f81ecc827ee8ca5d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022078885/0001213900-22-078885-index.htm"},{"fact_type":"governance_change","fact_key":"95013ba5ece6903b7a70a518afe851d77eee12db","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-11-25T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2022-11-22","item_codes_triggered":["5.03"],"summary_text":"Established Series B Preferred Stock with specific voting rights regarding Reverse Stock Split, Share Increase Proposal, and Adjournment Proposal."},"claim":"Allarity Therapeutics, Inc.: Established Series B Preferred Stock with specific voting rights regarding Reverse Stock Split, Share Increase Proposal, and Adjournment Proposal (effective 2022-11-22).","evidence_excerpt":"On November 22, 2022, the Board established the Series B Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-075271","anchor_url":"https://secwatch.observer/filing/0001213900-22-075271#claim-95013ba5ece6903b7a70a518afe851d77eee12db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022075271/0001213900-22-075271-index.htm"},{"fact_type":"governance_change","fact_key":"83e0ca4a737454f0cd561ff87886010a7d0f1348","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-11-25T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2022-11-22","item_codes_triggered":["5.03"],"summary_text":"Amended Section 12 of Certificate of Designation of Series A Convertible Preferred Stock to grant voting rights, with expiration on February 28, 2023."},"claim":"Allarity Therapeutics, Inc.: Amended Section 12 of Certificate of Designation of Series A Convertible Preferred Stock to grant voting rights, with expiration on February 28, 2023 (effective 2022-11-22).","evidence_excerpt":"On November 22, 2022, the Company amended Section 12 of the Certificate of Designation of Series A Convertible Preferred Stock to provide for voting rights. Subject to a 9.99% beneficial ownership limitation, the holders of Series A preferred stock shall have the right to vote on all matters presented to the stockholders for approval together with the shares of common stock, voting together as a single class, on an “as converted” basis using the “Conversion Price” (initially $9.906 per share before any adjustment) (rounded down to the nearest whole number and using the record date for determining the stockholders of the Company eligible to vote on such matters), except as required by law (including without limitation, the DGCL) or as otherwise expressly provided in the Company’s Certificate of Incorporation or the Certificate of Designations of Series A Convertible Preferred Stock. The voting rights described above shall expire on February 28, 2023, and thereafter holders of preferred","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-075271","anchor_url":"https://secwatch.observer/filing/0001213900-22-075271#claim-83e0ca4a737454f0cd561ff87886010a7d0f1348","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022075271/0001213900-22-075271-index.htm"},{"fact_type":"material_agreement","fact_key":"d34e699f9992705954ea736066331c513e881941","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-11-25T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"notes_offering","counterparty":"3i LP","effective_date":"2022-11-22","item_codes_triggered":["1.01"],"value_text":null},"claim":"Allarity Therapeutics, Inc. entered into Purchase Agreement with 3i LP (effective 2022-11-22).","evidence_excerpt":"ovember 22, 2022, the Company entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP. Under the\nPurchase Agreement, the Company has authorized the sale and issuance of three secured promissory notes, the first note in an aggregate","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-075271","anchor_url":"https://secwatch.observer/filing/0001213900-22-075271#claim-d34e699f9992705954ea736066331c513e881941","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022075271/0001213900-22-075271-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"7570c395e525f0aff4c3860c2552580be3f7417f","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-11-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-05-22","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2022-11-21","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"November 21, 2022,\nthe Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock\nMarket (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement of 1.00 per share\nunder the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities\nfor the last 30 consecutive business days from October 10, 2022 to November 18, 2022, the Company no longer meets the minimum bid price\nrequirement set forth in Listing Rule 5550(a)(2). The Notice is only a notific","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-075271","anchor_url":"https://secwatch.observer/filing/0001213900-22-075271#claim-7570c395e525f0aff4c3860c2552580be3f7417f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022075271/0001213900-22-075271-index.htm"},{"fact_type":"earnings_release","fact_key":"cc5531a14c1317c0b3ff3e01a8cf3fd765e955f2","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-11-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$5.0 million","period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-15","result_type":"reported_results","revenue_text":null},"claim":"Allarity Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $5.0 million.","evidence_excerpt":"Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-072851","anchor_url":"https://secwatch.observer/filing/0001213900-22-072851#claim-cc5531a14c1317c0b3ff3e01a8cf3fd765e955f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/0001213900-22-072851-index.htm"},{"fact_type":"executive_change","fact_key":"c2c9f7cddb","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-09-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-10-01","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jerry McLaughlin was appointed as director at Allarity Therapeutics, Inc..","evidence_excerpt":"To fill the vacancy, the Board appointed the following individual as a director of the Company, effective as of October 1, 2022: Class II Director : Jerry McLaughlin,","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-058902","anchor_url":"https://secwatch.observer/filing/0001213900-22-058902#claim-c2c9f7cddb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/0001213900-22-058902-index.htm"},{"fact_type":"executive_change","fact_key":"701419a780","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-07-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James G. Cullem was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class III Director : James G. Cullem, whose term will expire at the Company’s third annual meeting of stockholders to be held after December 2021","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-038536","anchor_url":"https://secwatch.observer/filing/0001213900-22-038536#claim-701419a780","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm"},{"fact_type":"executive_change","fact_key":"962529b2b6","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-07-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Roth was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class II Director : Dr. David Roth, whose term will expire at the Company’s second annual meeting of stockholders to be held after December 2021","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-038536","anchor_url":"https://secwatch.observer/filing/0001213900-22-038536#claim-962529b2b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm"},{"fact_type":"executive_change","fact_key":"d59cceb615","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-07-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas Jensen was appointed as Director at Allarity Therapeutics, Inc..","evidence_excerpt":"Class I Director : Thomas Jensen, whose term will expire at the Company’s first annual meeting of stockholders held after December 2021","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-038536","anchor_url":"https://secwatch.observer/filing/0001213900-22-038536#claim-d59cceb615","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022038536/0001213900-22-038536-index.htm"},{"fact_type":"executive_change","fact_key":"a114aad9b8","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-06-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-29","interim":true,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Joan Brown was appointed as interim Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"the Board appointed Joan Brown, the Company’s current Director of Financial Reporting, as the interim Chief Financial Officer of the Company effective as of June 29, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-036020","anchor_url":"https://secwatch.observer/filing/0001213900-22-036020#claim-a114aad9b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm"},{"fact_type":"executive_change","fact_key":"01aad30fbd","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-06-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-29","interim":true,"role":"interim Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"James Cullem was appointed as interim Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"the Board of Directors of the Company (the “Board”) appointed James Cullem, the Company’s current Chief Business Officer, as the interim Chief Executive Officer of the Company effective as of June 29, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-036020","anchor_url":"https://secwatch.observer/filing/0001213900-22-036020#claim-01aad30fbd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm"},{"fact_type":"executive_change","fact_key":"7b97e85420","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-06-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-27","interim":true,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Joan Brown","successor_named":true},"claim":"Jens Knudsen resigned as Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"Effective as of June 27, 2022, Jens Knudsen resigned from all positions in the Company, and all positions of its subsidiaries, including his role of Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-036020","anchor_url":"https://secwatch.observer/filing/0001213900-22-036020#claim-7b97e85420","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm"},{"fact_type":"executive_change","fact_key":"746eedc848","cik":1860657,"ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-06-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-29","interim":true,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"James Cullem","successor_named":true},"claim":"Steve Carchedi resigned as Chief Executive Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"Effective as of June 29, 2022, Steve Carchedi resigned from all positions in Allarity Therapeutics, Inc. (the “Company”), and all positions of its subsidiaries, including his role of Chief Executive Officer and as a director of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-036020","anchor_url":"https://secwatch.observer/filing/0001213900-22-036020#claim-746eedc848","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022036020/0001213900-22-036020-index.htm"}]}